Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Valaris Limited and Transocean Ltd. received unconditional clearance from the Brazilian competition authority (CADE) for their pending business combination. This marks the satisfaction of the final regulatory approval condition, with the merger expected to close in the fourth quarter of 2026 following a fifteen-day waiting period.
American Rebel's subsidiary, Champion Safe Company, is undergoing a major lean transformation and physical realignment of its Utah manufacturing facility. The initiative aims to eliminate bottlenecks, increase throughput, and create a more scalable operating platform to convert dealer demand into revenue. Management describes the project as a comprehensive factory redesign that goes beyond moving equipment to fundamentally improve production flow and efficiency.
StageWise Strategies Corp. completed a share exchange transaction to acquire 99.99% of TEG SPV LLC, an Uzbekistan-based entity, in exchange for 183,098,434 shares of common stock. Following the closing, TEG SPV became a subsidiary of the company, representing approximately 97.3% of the post-transaction outstanding shares. The company also changed its name to TEG Overseas, Inc. as part of the transaction.
Gemini Space Station, Inc. filed a prospectus supplement to register the potential resale of up to 7,142,857 shares of Class A common stock by an unnamed investor. The company receives no proceeds from these sales as they are secondary offerings by the selling stockholder, typically following a prior issuance such as an acquisition or private placement.
Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.
Liberty Global M&A Deal with DigitalBridge, TD Greystone Infrastructure and L&G
Liberty Global received EU Commission clearance for the previously announced sale of VodafoneZiggo's passive tower assets for €669 million. The transaction is part of a broader strategy to dispose of €1.2-1.4 billion in non-core assets to support the planned spin-off and listing of Ziggo Group in Amsterdam in 2027.
Counterparty
DigitalBridge, TD Greystone Infrastructure and L&G
Skyx Platforms Signs $12.5M M&A Deal with Deako, Inc.
SKYX Platforms Corp. completed its acquisition of Deako, Inc., which became a wholly-owned subsidiary. The consideration consisted of 25,000,000 shares of common stock, $4 million in cash, and an $8.5 million senior secured promissory note. Deako's former shareholders now own approximately 15.6% of the combined company.
Aptevo Therapeutics announced it will present data on its multispecific platform and CD40-directed portfolio at the SITC 2026 Annual Meeting. The presentation will focus on the platform's ability to coordinate innate and adaptive immune activity within the tumor microenvironment to overcome immunosuppression in solid tumors.
Integer Holdings M&A Deal with Kohlberg Kravis Roberts & Co. L.P.
Integer Holdings Corporation provided a status update on its pending acquisition by affiliates of KKR, noting that a special meeting of stockholders to approve the merger is scheduled for October 21, 2026. The company also disclosed that it has received several stockholder complaints and demand letters alleging disclosure deficiencies in its proxy statement and has issued supplemental disclosures to address these claims.
Pulse Biosciences Partnership with Clayman Thyroid Center at the Hospital for Endocrine Surgery
Pulse Biosciences has entered into a commercial and clinical partnership with the Clayman Thyroid Center to utilize the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules. The collaboration involves the commercial use of the system at the Tampa-based center and a joint effort to collect real-world clinical outcomes and conduct formal studies on nsPFA energy utility.
Counterparty
Clayman Thyroid Center at the Hospital for Endocrine Surgery
Data443 Risk Mitigation, Inc. announced the general availability of Vaikora, its AI runtime enforcement and control platform designed to govern AI agent actions and data flows in real-time. The platform provides inline controls to allow, block, or constrain AI tool calls and agent-to-agent communications, addressing a security gap as enterprises move autonomous AI agents into production.
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
Flex Ltd. completed its acquisition of EPC Power Corp., a provider of power conversion solutions for data centers and grid applications, to strengthen its Cloud and Power Infrastructure portfolio. To fund the transaction, Flex entered into a $1.1 billion senior bridge credit facility and borrowed the full amount on October 14, 2026. The acquisition is part of Flex's strategy to address AI infrastructure power demands ahead of its planned spin-off of the segment into a new company, Axiom Solutions International, Inc.
Value
$1.1B
Counterparty
EPC Power Corp.
“EPC Power adds differentiated power conversion and grid-forming technology to our capabilities across power, cooling and compute. Together, we can help customers address the growing power demands of AI infrastructure with more efficient, resilient and integrated solutions.”
Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.
OneMedNet Corporation has regained compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from September 29, 2026, through October 12, 2026. Nasdaq has officially closed the matter, resolving the deficiency notice originally issued on April 14, 2026.
Fermi Inc. entered into a binding 15-year turnkey lease agreement with TensorWave for 222 MW of total power capacity at its Project Matador site. The contract is expected to generate $6.5 billion in revenue over the initial term and includes investment-grade credit support from AMD. Phased delivery of the capacity is scheduled to begin in Q4 2027 and complete in early 2028.
Strive, Inc. announced the exercise of 273,493,909 traditional warrants between October 12 and October 13, 2026, resulting in the issuance of 13,674,703 shares of Class A common stock for gross proceeds of $369.2 million. Following these exercises, no warrants from the company's PIPE transaction remain outstanding. Additionally, the company disclosed the purchase of 2,822 bitcoin for approximately $235 million during the same period.
Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.
Brightline Interactive regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days. The company achieved this by implementing a 1-for-8 reverse stock split effective September 28, 2026, following a prior delisting notice. The matter is now closed and the company's stock continues to trade on the Nasdaq Capital Market under the symbol BTLN.
Faraday Future Intelligent Electric Divestiture to FF EAI Robotics Ecosystem Inc. for $200M
Faraday Future Intelligent Electric Inc. (FFAI) entered into a definitive agreement to sell its robotics business to FF EAI Robotics Ecosystem Inc. (FFR) for an aggregate consideration of approximately $200 million. The transaction is an all-stock deal where FFAI will receive FFR common and preferred stock, resulting in FFAI holding a 65.7% controlling interest in FFR upon closing. The deal allows FFAI to monetize its robotics assets while maintaining majority control of the newly pure-play robotics entity.
FF EAI Robotics Ecosystem Signs $200M M&A Deal with Faraday Future Intelligent Electric Inc.
FF EAI Robotics Ecosystem Inc. entered into a definitive transaction agreement to acquire the robotics business of its majority stockholder, Faraday Future Intelligent Electric Inc. (FFAI), for approximately $200 million. The all-stock deal involves the issuance of common and preferred shares at a valuation of $2.246 per share, making the company a pure-play humanoid and bionic robotics entity. The transaction is expected to close by the end of October 2026, resulting in FFAI holding approximately 65.7% of the combined company.
Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.
Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.
Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.
FortuneX Acquisition Signs $525M M&A Deal with WT Realty Group Inc.
FortuneX Acquisition Corporation entered into an amendment to its existing business combination agreement with WT Realty Group Inc., reducing the aggregate merger consideration from $600 million to $525 million. The revised consideration consists of 52.5 million shares of common stock at a reference price of $10.00 per share. This update modifies the terms of the pending SPAC merger originally announced in September 2026.
Pioneer Acquisition I Signs $300M M&A Deal with Green AI Cloud, Inc.
Pioneer Acquisition I Corp (SPAC) has entered into a definitive business combination agreement with Green AI Cloud, Inc., a Stockholm-based clean energy AI supercompute platform. The transaction values Green AI Cloud at a pre-money equity value of $300 million and will result in the company becoming a publicly traded entity on the Nasdaq. Green AI Cloud focuses on sustainable AI data centers powered by 100% renewable energy with heat recovery systems.
Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.
LogicMark, Inc. completed its merger with Langham Project LLC, with the company surviving as a wholly owned subsidiary of Langham. Shareholders of LogicMark common stock are entitled to receive $1.31 per share in cash as consideration for the transaction.
CID Holdco Signs $65M M&A Deal with BladeRanger Ltd.
CID HoldCo, Inc. (doing business as Dot Ai) completed the acquisition of 100% of Envoy Technologies, Inc. from BladeRanger Ltd. in an all-stock transaction valued at approximately $65 million. The deal adds an electric vehicle carsharing business to Dot Ai's portfolio and is expected to help the company regain compliance with Nasdaq's minimum stockholders' equity requirement.
Lattice Semiconductor M&A Deal with AMI TopCo, Inc.
Lattice Semiconductor Corporation filed an amendment to its previous 8-K to provide required historical audited and unaudited financial statements and pro forma financial information regarding its completed acquisition of AMI TopCo, Inc. The acquisition was originally completed on July 27, 2026, following a definitive merger agreement signed in May 2026.
Barrel Energy's Happy Traps business unit is launching a new line of eco-friendly cleaners and degreasers under the brand name 'Almighty Cleaners' in October 2026. The products are manufactured using by-products recovered from the company's existing cooking oil and grease-trap waste collection operations. This initiative marks the company's expansion from waste collection into the commercialization of recycled materials.